These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36817591)

  • 1. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
    Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
    Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
    Faggiano A; Di Somma C; Ramundo V; Severino R; Vuolo L; Coppola A; Panico F; Savastano S; Lombardi G; Colao A; Gasperi M
    Endocrine; 2011 Jun; 39(3):283-7. PubMed ID: 21445714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
    J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism].
    Misiorowski W
    Endokrynol Pol; 2005; 56(6):871-5. PubMed ID: 16821204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab increases spine bone density in women with anorexia nervosa: a randomized clinical trial.
    Haines MS; Kimball A; Meenaghan E; Santoso K; Colling C; Singhal V; Ebrahimi S; Gleysteen S; Schneider M; Ciotti L; Belfer P; Eddy KT; Misra M; Miller KK
    Eur J Endocrinol; 2022 Nov; 187(5):697-708. PubMed ID: 36134902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis.
    Sharma S; Shankar V; Rajender S; Mithal A; Rao SD; Chattopadhyay N
    Front Endocrinol (Lausanne); 2024; 15():1426490. PubMed ID: 39257899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
    Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
    PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment in muscle strength and its determinants in primary hyperparathyroidism: A study in postmenopausal women.
    De Martino V; Pepe J; Biamonte F; Colangelo L; Di Giuseppe L; Nieddu L; Occhiuto M; Minisola S; Cipriani C
    Bone; 2023 Jan; 166():116604. PubMed ID: 36347434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Lyu H; Jundi B; Xu C; Tedeschi SK; Yoshida K; Zhao S; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 May; 104(5):1753-1765. PubMed ID: 30535289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
    Ardawi MS; Al-Sibiany AM; Bakhsh TM; Rouzi AA; Qari MH
    Osteoporos Int; 2012 Jun; 23(6):1789-97. PubMed ID: 22041864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Baseline PTH Influence Recovery of Bone Mineral Density, Trabecular Bone Score and Bone Turnover Markers? A Prospective Study Following Curative PArathyroidectomy in Primary Hyperparathyroidism.
    Shetty S; Cherian KE; Shetty S; Kapoor N; Jebasingh FK; Cherian A; Hephzibah J; Chandramohan A; John RA; Asha HS; Paul MJ; Manipadam MT; Abraham DT; Thomas N; Paul TV
    Endocr Pract; 2020 Dec; 26(12):1442-1450. PubMed ID: 33471736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism.
    Miyaoka D; Imanishi Y; Kato E; Toi N; Nagata Y; Kurajoh M; Yamada S; Inaba M; Emoto M
    Endocrine; 2020 Sep; 69(3):642-649. PubMed ID: 32621048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Biochemical, and Radiological Profile of Normocalcemic Primary Hyperparathyroidism.
    Palermo A; Naciu AM; Tabacco G; Falcone S; Santonati A; Maggi D; D'Onofrio L; Briganti SI; Castellitto D; Casini A; Pedone C; Lelli D; Fabbri A; Bilezikian JP; Napoli N; Pozzilli P; Manfrini S; Cesareo R
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32271382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
    Cesareo R; Di Stasio E; Vescini F; Campagna G; Cianni R; Pasqualini V; Romitelli F; Grimaldi F; Manfrini S; Palermo A
    Osteoporos Int; 2015 Apr; 26(4):1295-302. PubMed ID: 25524023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TBS as a Tool to Differentiate the Impact of Antiresorptives onCortical and Trabecular Bone in Children With OsteogenesisImperfecta.
    Rehberg M; Winzenrieth R; Hoyer-Kuhn H; Duran I; Schoenau E; Semler O
    J Clin Densitom; 2019; 22(2):229-235. PubMed ID: 30309730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Szymczak J; Bohdanowicz-Pawlak A
    Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.